Roy E. Strowd III, MD

Articles by Roy E. Strowd III, MD

Chemotherapy for Treatment of Grade II Gliomas

ByRoy E. Strowd III, MD,Matthias Holdhoff, MD, PhD,Stuart A. Grossman, MD

December 15th 2014

In this article, we provide a brief overview of the management of grade II astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas-the three most heavily encountered and studied of the low-grade gliomas.

Latest Updated Articles

Chemotherapy for Treatment of Grade II Gliomas
December 15th 2014

Trending on CancerNetwork

Durvalumab Plus BCG Earns FDA Approval For High-Risk NMIBC

FDA Approves Pivekimab Sunirine in Rare Hematologic Malignancy

Toripalimab Regimen Improves EFS, MPR Rate in Stage II/III NSCLC Trial

This Week in Breast Cancer: Camizestrant Delay, Bria-IMT Data, Recurrence Test

87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1